Oruka Therapeutics (ORKA)

Executive Summary

Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for autoimmune and inflammatory diseases, with an initial emphasis on dermatology. Its lead product candidate targets moderate-to-severe plaque psoriasis, leveraging a differentiated mechanism to address significant unmet need in the dermatology market. The company went public and is advancing its pipeline through clinical trials, with the goal of generating pivotal efficacy and safety data. Oruka’s strategy centers on building a robust pipeline of targeted biologics for chronic inflammatory conditions, positioning itself as a potential leader in the dermatology biologics space. Given the large psoriasis market and the need for novel treatments with improved dosing and efficacy, Oruka’s progress is closely watched by investors and clinicians alike.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data readout for lead plaque psoriasis candidate50% success
• Q2 2027Initiation of Phase 3 pivotal trial for lead candidate70% success
• Q1 2027Preclinical data for next-generation pipeline asset40% success